# A Safety and Tolerability Study of BPR-30221616 Injection in Healthy Subjects

> **NCT06760455** · PHASE1 · RECRUITING · sponsor: **Chengdu Brilliant Pharmaceutical Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** BPR-30221616 Injection
- **DRUG:** Sodium Chloride Injection

## Key facts

- **NCT ID:** NCT06760455
- **Lead sponsor:** Chengdu Brilliant Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2026-01-24
- **Final completion:** 2026-12-05
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06760455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06760455, "A Safety and Tolerability Study of BPR-30221616 Injection in Healthy Subjects". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT06760455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*